Source: Simply Wall Street
Elanco Animal Health is attracting investor attention following a recent decline in its stock price, despite stronger long-term performance. As of October 13, 2026, Elanco shares traded at $22.41, with a one-year total shareholder return of 10.83%. According to Simply Wall St, some investors believe the company is undervalued by approximately 28%, estimating its fair value at $31.21 per share.
Elanco’s diversified portfolio of companion animal and livestock products, strategic product launches, and efforts to streamline operations contribute to its positive outlook. The divestment of noncore businesses, including its Aqua division, has helped reduce debt and increase investment capacity. Operational improvements and a stronger product mix could also support profit margin expansion beginning in 2026.
However, potential risks include unfavorable foreign exchange movements and slower-than-expected adoption of new products, including Zenrelia and Credelio Quattro. Investors must weigh these uncertainties against the company’s long-term growth prospects and financial outlook.
Read the full story HERE: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/why-elanco-animal-health-elan-is-getting-attention-now